Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS: iBrands Corporation Enters Into Distribution Agreement With Medical Supply Group
http://www.globenewswire.com/news-release/2020/03/23/2004791/0/en/iBrands-Corporation-Enters-Into-Distribution-Agreement-With-Medical-Supply-Group.html
Supply Group
Email Print Friendly Share
March 23, 2020 09:00 ET | Source: iBrands Corporation
LAS VEGAS, March 23, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) ("the Company"), a diversified holding and branding company, announces that it has, through its wholly owned subsidiary iBrands Farms, entered into a distribution agreement with Standard Medical Equipment Systems respectively.
Standard Medical Equipment Systems or Standard Med, is a certified minority (MBE) and Veteran (SDVOSB) owned company that was certified by the Center for Veteran Enterprises to deliver high quality medical devices and laboratory equipment. The company has three offices in New York, Maryland, and Florida.
iBrands Farms has over 40 retail industrial hemp derived cannabidiol (commonly known as CBD) products ranging from smokables, isolate by the ounce, topicals, edibles, and dog treats. Additional products included in the agreement is the unique nutraceutical product line of NanoStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, and ProJuvenol.
"We are excited about the potential distribution opportunity of our line of product offerings that include a range of CBD products for humans and pets, as well as unique nutraceutical products that feature nanotechnology delivery systems that Standard Med is in a great position to provide given their long history of success in the medical equipment supply industry," said Hugh Kelso, CEO of iBrands Corporation.
"We are thrilled to have the opportunity to collaborate with iBrands Corporation. We anticipate a great synergistic effect, as we forge a path forward together with innovative, world class healthcare products, that delivers the standard of excellence in healthcare for all," said Anthony Goodesmith, CEO of Standard Med.
Mr. Goodesmith served as a highly decorated combat signaler/communications officer in the U.S. Army and New Jersey National Guard for over 18 years. His units took part in Operation Desert Storm, and several other military campaigns after the 9/11 U.S. Terror Attacks (Operations Enduring Freedom and Noble Eagle). He received his B.S. in Marketing and Media Arts from Long Island University, NY, and his Master’s degree in Biotechnology Management from The University of Maryland University College (UMUC). Mr. Goodesmith has been working in the health care, medical industry in sales and management for over 20 years at several Fortune 500 pharmaceutical and medical device companies such as Eli Lilly & Company, Solvay Pharmaceuticals, AstraZeneca, and Roche Laboratories, respectively.
About iBrands Farms
iBrands Farms is a vertically integrated agribusiness focused on the production of hemp derived products with naturally occurring cannabinoids. Our mission is to efficiently deliver the highest quality industrial hemp-derived cannabidiol products to our customers, both retail and B2B.
The company can be found at: www.ibrandsfarms.com
About Standard Medical Equipment Systems
Standard Medical Equipment Systems is a certified minority (MBE) Veteran (SDVOSB) owned company certified by the Center for Veteran Enterprises, (CVE). Standard Med was established in 2005 to deliver high quality medical devices and laboratory equipment.
The company can be found at: https://www.standardmedicalsystems.com/
Look up FailColors posting history
he's a complete moron
this one can do better than IBIO imo
in for 1M shares this morning, lets go
NEWS: Global Technologies, Ltd is Pleased to Update Shareholders on its Recent Corporate Progress
http://www.globenewswire.com/news-release/2020/02/26/1991260/0/en/Global-Technologies-Ltd-is-Pleased-to-Update-Shareholders-on-its-Recent-Corporate-Progress.html
ST. PETERSBURG, FL, Feb. 26, 2020 (GLOBE NEWSWIRE) -- ?Global Technologies, Ltd (OTC Pink: GTLL), a former technology portfolio company that acquired nascent technology and related innovations, inventions and IP assets to enhance their growth and development is pleased to provide today’s shareholder update on the Company’s current progress and operations.
Over the past six months, the Company has worked to complete its two-year audit for fiscal years 2018 and 2019 and stub period for the six months ended December 31, 2019. The Company is at the end stage of the audit and anticipates the filing of its Registration Statement on Form 10 during the month of March. By filing the Form 10, the Company will become a fully reporting entity with the Securities and Exchange Commission thus increasing transparency for its shareholders.
Prior Operational History
From inception until March 2011, Global Technologies was a technology portfolio company that acquired nascent technology and related innovations, inventions and IP assets to enhance their growth and development. The Company built revenues and asset value through a model of continuous growth, income from or sale of its portfolio holdings, and technology licensing or distribution agreements.
The Company invested primarily in innovative and promising clean/renewable energy or bio-tech technologies that had reached the stage in the critical Technology Development & Demonstration phase of the Innovative Cycle, which includes Prototype, Demonstration and Market Analysis. In March 2011, the Company abandoned its operations.
Future Operations
The Company’s current business plan is to seek a merger candidate for future operations. In implementing a structure for a particular business acquisition, we may become a party to a merger, consolidation, reorganization, joint venture, or licensing agreement with another company or entity. As part of our investigation, we expect to meet personally with management and key personnel, visit and inspect material facilities, obtain independent analysis of verification of certain information provided, check references of management and key personnel, and take other reasonable investigative measures, to the extent of our limited financial resources and management expertise. The manner in which we participate in an opportunity will depend on the nature of the opportunity, the respective needs and desires of both parties, and the management of the opportunity.
At present, the Company has not identified a target acquisition, but anticipates upon filing the Form 10 we will be presented with several candidates.
The company also wishes to remind all shareholders and persons of interest that Global Technologies, Ltd will be making announcements and updates via social media. Updates can be found at our social media channel on Twitter at: https://www.twitter.com/GlobalTechGTLL.
Looks like it was one big market sell this morning, time to go back up
NEWS: SPO Global and Gerpang Healthcare Group Complete Merger Agreement
https://www.otcmarkets.com/stock/SPOM/news/SPO-Global-and-Gerpang-Healthcare-Group-Complete-Merger-Agreement?id=254298
TAMPA, Fla., Feb. 19, 2020 (GLOBE NEWSWIRE) -- SPO Global, Inc. (OTC Markets: SPOM) (the “Company”), has completed its previously announced merger with Gerpang Healthcare Group (“Gerpang”) of Shandong, China.
The acquisition closed on February 19, 2020, and, as previously discussed, all officers and directors of SPO Global have been replaced by the management of Gerpang. Mr. Lu Fengyou has been appointed CEO and Mr. Liangjian Peng has been appointed Secretary. Mr. Fengyou Lu, the CEO and founder of Gerpang Healthcare Group, has 24 years of business experience in the pharmaceutical market in the Greater China region and has successfully run four foreign-funded enterprises and large private enterprises. He is also a Chairman of Pioneer Zhongrun Biotechnology Co., Ltd. and CEO of Canada SOTA Biomedical Investment Co., Ltd. Mr. Lu is a strategic partner of Pioneer Zhongrun (Beijing) Stroke International Specialist Hospital. Previously, Mr. Lu was a Professor of the School of Pharmaceutical Science of Shandong University.
As part of the merger, a total of $1.23 million of existing debt was cancelled. Of this amount, $650,000 of debt previously assumed by the Company from Wine Stream was cancelled and 19.4 million shares were returned from Wine Stream shareholders in exchange for the return of IP, licensing and revenue participation rights. Remaining Company debt holders agreed to cancel $580,000 million in debt and convert $1,100,000 of debt, bringing the total shares outstanding in the Company at the time of merger to 42,000,000. Gerpang Shareholders were issued 160,000,000 shares of the Company’s common stock bringing the total shares outstanding to 202,000,000 with no convertible debt post-merger.
The Company’s CIO, Saeb Jannoun, stated: “We were successful in working with our debt holders to complete this merger with Gerpang Healthcare. The merger marks a very exciting and important point in the Company’s history.”
About SPO Global Inc. (OTC Markets: SPOM). The Company is a diversified holding company whose strategy is to acquire interests in a range of profitable ventures. Gerpang Healthcare Group (www.gerpanghealthcare.com), is located in Jinan Pharma Valley Industrial Park, High-tech District. It is an innovative technology-based private and high-tech enterprise. The main business scope of the Gerpang includes bio-pharmaceutical R&D, development and sales of medical information software, medical high-tech introduction, production and sales of medical quality supplies, dietary supplements, medicine and agents, as well as sales of medical equipment supplies. In addition to having a staff of over 220 people, Gerpang has more than 10 international and national patents and its annual turnover is approximately RMB 1 billion.
In the past five years, Gerpang has established strategic partnerships with various universities in biomedicine in Toronto, Montreal, Boston, New York and Connecticut, and has established a wide range of government resource management and business contacts. The relationships have resulted in multi-level investments by Gerpang in more than 20 projects.
Company Disclaimers: As a "penny stock" Company, within the meaning of federal and state securities law, SPO Global, Inc. may not avail itself of the Safe Harbor provisions as identified in the Private Securities Litigation Reform Act of 1995. However, SPO Global, Inc. provides the following disclaimer and warning to protect our shareholders, prospective investors and the public at large by alerting them to the risks and uncertainties involved with any investment, and the need to perform their own due diligence and assessment.
Reinstatement with 3 new officers
Retired Judge Phillip Larocca
Philip Moreb
Bridget Moreb
let's do some digging.
i believe funnyg has already found a link with these guys and Providence Care Inc.
name changed back to the original name of the company before it changed to PharmaRoth.
https://www.prnewswire.com/news-releases/fero-industries-inc-changes-name-to-pharmaroth-labs-inc-199895711.html
not sure what's going on here
i think the announcement is on wed, the 19th
reinstatement with new officer - Alan Shinderman
NEWS: HYPERTENSION DIAGNOSTICS Inc., "HDII" Shareholder Update
https://www.accesswire.com/576075/HYPERTENSION-DIAGNOSTICS-Inc-HDII-Shareholder-Update
TORONTO, ON / ACCESSWIRE / February 11, 2020 / The Company HDII (OTC PINK:HDII), at this time would like to inform all Shareholders that the Company, Gerpang Healthcare Group, located in Jinan Pharma Valley will not be Merging into Hypertension Diagnostics Inc., at this time. Gerpang Healthcare Inc. has decided to enter into an Agreement with a different Company due to the recent Control Dispute caused by previous Management, Kenneth Brimmer.
Liangjian Peng the current CEO, was able to bring the Company current with the State of Domicile, OTC Markets, and the Company's Transfer Agent after being left dormant for many years by previous Management. Only, to be met with false claims from Mr. Brimmer regarding his position with the Company.
Unfortunately, due to Kenneth Brimmer, the previous CEO of the Company Hypertension Diagnostics Inc., there is now a "Control Dispute" claim to the Company.
New Management Liangjian Peng, the current CEO of Hypertension Diagnostics Inc. will be filing a Legal Action against Mr. Brimmer in regards to his unlawful claims.
Mr. Peng the current CEO stated, "Mr. Kenneth Brimmer has deliberately left Hypertension Diagnostics Inc. "HDII" dormant for many years, causing financial burden to both, the Company and its Shareholders. Furthermore, his false claims have no merit. I as the current CEO, currently have all supporting documentation that not only reflect absolute proof that Mr. Brimmer's claims are false, but evidence that he continues to financially burden the Shareholders of the Company and the Company itself deliberately."
NEWS: Enertopia Provides Company Update
https://ih.advfn.com/stock-market/USOTC/enertopia-pk-ENRT/stock-news/81724408/enertopia-provides-corporate-update
Kelowna, BC, Canada -- February 11, 2020 -- InvestorsHub NewsWire -- Enertopia Corporation (ENRT) on the OTC (the "Company" or "Enertopia") is pleased to provide this ongoing update.
Further to the Company's news release of December 30th 2019, it continues to explore strategic business combinations and is in early talks with respect to such joint ventures or other strategic alliances in the clean energy market place and will provide further details as discussions warrant.
These ongoing talks have included ways to monetize future production from the Company's Clayton Valley, Nevada project and if successful would allow the Company a non-dilutive path for the next step forward.
The Company believes we are in the first inning of what is and will be the transformation of the World's transportation system currently close to 100% dependent on hydrocarbons. But already we are seeing the first nascent steps forward on the EV side where over the past two years EV's are growing in their percentage of market share while Internal Combustion Engines (ICE's) have fallen in aggregate demand two years running and this looks to be the third year in a row of falling demand.
Roskill put out a recent update in January on lithium-ion demand growth and future expectations.
"Between 2015 and 2018, shipments of lithium-ion batteries have increased by 24%py in terms of battery capacity, reaching over 148,000MWh. In comparison battery capacity of NiMH batteries shipped totaled below 10,000MWh and NiCd batteries below 1,000MWh in 2018. There has been significant investment by incumbent and new battery producers into constructing additional manufacturing capacity to meet demand. Major battery producers plan to invest over US$50Bn in expanding manufacturing capacity over the next 5 years in China, the USA and Europe, which is scheduled to increase annual battery capacity production to over 1.2TWh by 2030.
Automotive applications accounted for over 70% of total lithium-ion battery shipments in 2018, compared to just 43% in 2015 and 6% in 2010. The growth in automotive applications is forecast to maintain a rapid pace, with shipments increasing by in excess of 30%py through to 2030."
The President wishes to acknowledge the many emails and phone calls from shareholders over the past month. And with respect to shareholder questions below are the questions I can answer at this time.
1) What is the current share structure:
Shares issued and outstanding
128,471,700
Warrants
17,668,459
Options
7,320,000
Fully diluted
153,460,159
2) Plans for rollback:
The Company has no current plans for a share rollback.
3) Projected revenue:
The Company has not completed any 3rd party engineering reports with respect to potential revenue scenarios at this time.
4) Are we engaged with Tesla or similar companies:
The Company is not engaged with Tesla or similar companies at this time.
5) Status of NDA's:
The Company has signed multiple NDA's with respect to the work we have been doing with respect to the synthetic brine solutions work completed in 2019 and they are in good standing.
6) Does the Company hold Toxic Debt:
No, the Company does not have any toxic debt
7) T1 or aftermarket financings:
The Company has not issued any equity or debt after the market close. Further to this the Company always files press release and subsequent 8K with any financing activities. Shareholders and stakeholders are always best informed by visiting the OTC, SEC and Company websites for information about the Company.
8) Are you able to confirm that the brine solution would change the battery industry in much the same way the silicon chip transformed the electronics industry:
The Company continues to work on the brine solution and believes it could have a material impact on where companies will source future Lithium source material for EV's and other battery needs. A better analogy might be what fracking did to the oil and natural gas industry. Land that used to go for a few thousand dollars per section ended up going for thousands of times that number due to the changes in technology.
There are several companies today at the pilot plant stage testing where a technology breakthrough could impact the company's with claystone resources in Nevada in the same way!
"We will continue to put relevant news updates out as soon as possible as we move forward to reach our milestones, Stated President Robert McAllister."
Lazar will file a 15-12G shortly after being granted custo, thereby going dark and foregoing any sec reporting obligations. it's his MO.
Good R/R here imo
Could the sharp decline in stock price be caused by the directors selling their shares in the company?
today saw a slew of directors resign...would they be the reason for the decline?
New CEO incoming: Warren Mosler
On January 31, 2020, Mr. Warren Mosler was appointed as Chairman of the Board, Chief Executive Officer, Chief Financial Officer, President, treasurer and secretary of the Company. Mr. Mosler is an American economist and theorist. Presently, in addition to his new role with the Company, Mr. Mosler owns and operates Valance Co., Inc. He is founder of Mosler Automotive and a co-founder of the Center for Full Employment and Price Stability at the University of Missouri-Kansas City. The founder of what has been popularized as Modern Monetary Theory, in 2014 he was appointed Visiting Professor at the University of Bergamo, Italy. He also co-founded AVM, L.P., a broker-dealer providing financial services to institutional investors, and the Illinois Income Investors family of investment funds, which he remained involved with until 1997.
Additionally...
thank you for confirming this Jon.
lol but you said jon confirmed it was real, now he confirmed its fake?
NEWS: Enzolytics Comments on Recent Market Activity and Shareholder Update
https://www.accesswire.com/575576/Enzolytics-Comments-on-Recent-Market-Activity-and-Shareholder-Update
DALLAS, TX / ACCESSWIRE / February 6, 2020 / Enzolytics- (OTC Pink Sheet-ENZC) was notified by FINRA that an unauthorized press release titled, "Enzolytics Inc., Launches Coronavirus Prevention Kit" was distributed to the public. Enzolytics and its management had no knowledge of this press release in any manner, and disavows any information contained in this press release. The company does not have a "Coronavirus Prevention Kit" and finds the claim reckless and fraudulent.
Enzolytics, Inc., Inc. is diligently working to bring its filings current and continue with its initiatives for the commercialization of its proprietary proteins for the treatment of HIV.
Enzolytics flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. ITV-1 has also been shown to have anti-viral efficacy. Enzolytics continues to work with its Bulgarian partner, Immunotech Laboratories, BG, to complete the validation of the production process to submit the final documents to the Bulgarian drug agency in order to obtain registration.
what do you mean? there are posters here saying the dude confirmed it was real, so would you not want proof of this?
you don't think people have tried to do just that? incorrect email address and now this supposed real one.
it's not even that hard of a request to do.
all you guys gotta do is provide proof that Jon confirmed the authenticity of the PR and this is trading higher
yet you guys can't even seem to do that
it's not that much to ask for
in email?
again, any screenshots of said email?
and yes i've sent an email to him, waiting on response
i know that email works, dumb silly mistake by the company
now, is the PR legit?
again, if you can provide proof that it's real, then it's game on.
otherwise, it's where it's at now.
provide proof that the CEO responded from that email addy saying it's a legit PR
it's going down bc everyone is skeptical of its validity.
the email on the pr doesn't work, neither does their website.
one hint of validity and it's a race to .01...but no way to find out.
email doesn't work - jonp@connectyx.com
just got a return to sender email
NEWS: Connectyx Receives a 7 Million USD Funding Commitment From a Chinese Institution for Personal Early Response System Software (PERS)
https://www.businesswire.com/news/home/20200206005108/en/
STUART, Fla.--(BUSINESS WIRE)--Connectyx Technologies, Inc. (Pink Sheets: CTYX) is pleased to announce that it has received a 7 million dollar funding commitment from a Chinese based financial institution to establish an early virus detection software that can be programmed through our Personal Early Response System medical alert platform. The synchronization of the software will be simplified in an application based algorithm using our PERS upgrade software called Medical Alert 3. Our software will help in early detection to prevent the spread of airborne pathogens. Unlike the previous Medical Alert programs, Medical Alert 3 will focus on different characteristics of airborne contaminants and pathogens that are associated, but not limited to particular airborne threats such as bird flu or common human type viruses such as the coronavirus.
"We are honored and grateful for this opportunity," says CEO Jon Pevzner. We look forward to having our medical alert systems utilized everyday all over the world, to help the whole of humanity.
The funding will be designated throughout three phases. Research, Testing, and Development. At the conclusion of the development stage connectxy will enter into negotiations to expand it's medical alert program system and establish a headquarter in Shanghai, one of the bustling financial capitals of the world .
Connectyx Technologies Holdings Group, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical expenses transcription, disease management, revenue cycle management, and medical consulting-billing.
8K posted: update
https://ih.advfn.com/stock-market/USOTC/petlife-pharmaceuticals-inc-PTLF/stock-news/81638612/current-report-filing-8-k
Petlife Pharmaceuticals, Inc.’s 51% owned company, The Maye International Group Sarl (“TMIG”), anticipates planting its initial hemp crop this spring. Upon the successful harvest this first crop during the summer, TMIG expects it will then expand its planting of hemp to further meet the growing demand for hemp products. TMIG will be overseeing the planting and harvesting while Petlife’s joint venture partner, Red Rock Alternative Fund LLC, will be securing the sales of the hemp products. The Maye International Group anticipates that the first crop will be sold to the international market during the summer of 2020. More details will follow as the planting is completed.
Looks like one big seller market sold and brought down the price, now looks to be recovering a bit.
NEWS/8K: Arista Financial Corp. Announces 2020 Growth Plans
https://www.sec.gov/Archives/edgar/data/1498122/000121390020001754/f8k012220ex99-2_aristafin.htm
Company Appoints an Experienced Chief Financial Officer
Arista’s Mobility Subsidiary to Target Carsharing Market, Estimated at $12 Billion by 2024
Short Hills, New Jersey, January 27, 2020 -- Arista Financial Corp., a financial service holding company (the “Company”) (OTC: ARST), announced today that it has appointed William J. Caragol as its new Chief Financial Officer. Mr. Caragol has extensive experience with growth stage microcap companies in finance, mergers and acquisitions, business development and accounting.
The Company had previously announced that it intends to enter the mobility industry through a newly created majority owned subsidiary, Arista Mobility Group Ltd. (“AMG”) and with the addition of Mr. Caragol, it now will move forward with the formal incorporation of this entity in anticipation of commencing its activities in the mobility industry. The Company has evaluated the Carsharing Market, which has been estimated to grow to $12 Billion by 2024 (by Global Market Insights, Inc.), and has determined that the expertise and experience of the AMG management group combined with the Company’s experience in the transportation industry, provides an outstanding opportunity for growth in 2020 and beyond.
Arista Financial Corp. currently operates in the transportation industry through its wholly owned subsidiary, Arista Capital, which provides trucks mostly to owner-operators that would otherwise be unable to obtain these vehicles. The Company sees a similar opportunity through AMG to provide vehicles on a rental basis to drivers for ridesharing and delivery companies such as Uber, Lyft and Door Dash, who otherwise are unable to obtain these vehicles through other sources.
Mr. Patrizio, CEO of Arista Financial commented that “Bill Caragol is an excellent addition to the Arista team as he brings a wealth of financial knowledge and public company experience to this role. I am very confident that this tremendous addition to the Executive Management team will accelerate our move into the next chapter of the Company’s growth. “
The Company expects to provide further details regarding its plans for the mobility industry soon.
About Arista Financial Corp.
Arista Financial Corp. is a publicly traded holding company (ARST) which seeks to take advantage of the current vehicle finance marketplace through its wholly owned subsidiary, Arista Capital.
To learn more about Arista Financial Corp., visit www.aristafinancial.com.
Name Change on SOS
NDT Pharmaceuticals
https://esos.nv.gov/EntitySearch/BusinessInformation?businessid=589769
BRCH name and symbol change
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Old: BRCH Bull Run Capital Holdings, Inc. Common Stock
New: BUDT BUDDING TIMES, INC Common Stock
Additionally per the website:
https://www.bullruncapitalholdings.com/
January 8, 2020
GENERAL INFORMATION
?
We are a Non-SEC Reporting company and therefore not subject to the reporting requirements of the Exchange Act. However, we are posting this Information Statement on our website to provide current information publicly regarding our most recent activities.
?
OTHER EVENTS -AMENDMENT TO ARTICLES OF INCORPORATION OR BYLAWS
Effective January 8, 2020, the Company’s corporate name was changed from “Bull Run Capital Holdings, Inc.” to “Budding Times, Inc.” (the “Name Change”). The Name Change was effectuated by filing Certificate of Amendment to the Articles of Incorporation with the Nevada Secretary of State (the “Certificate of Amendment”). The Company has filed a corporate action with FINRA to change the name of the Company and its ticker symbol. However, FINRA has not yet announced the name change or released the new ticker symbol into the marketplace. The new CUSIP number for the Company is 11884B 103. The Company also amended and restated its Bylaws (the “Amended and Restated Bylaws”) to reflect the Name Change.
The Name Change does not affect the rights of the Company's stockholders and there were no changes to the Articles of Incorporation or the Amended and Restated Bylaws other than to reflect the Name Change. The Company’s common stock, par value $0.001 per share (the “Common Stock”), will continue to trade in the Pink market tier on the OTC MarketPlace.
?
thanks for following up.
i got duped like a little puppy dog on last week's article of merger fraud (BLPG), so these have to be taken with some considerable grains of salt now.
horrible what's going on with nvsos and their lack of detail there.
why would i include her email in posts if i haven't already gotten confirmation from her?
go on right ahead, i have her emails in my inbox as well.
today's filing was fake, but there is still a merger coming after the custodian has already reinstated the entity in NV.
just gotta be wary of those articles of merger filings on SOS, i've gotten duped badly before, which is why i had to confirm with the custodian of its authenticity, which turned out to be fake.
Ask the custodian yourselves if you want proof that the articles of merger are real or fake.
rhonda@smallcapcompliance.com
how so? you can ask rhonda keaveney yourself.
rhonda@smallcapcompliance.com
she is the custodian.
so go ahead and disprove my post.